Cubist Pharms Llc Company Profile

What is the competitive landscape for CUBIST PHARMS LLC

CUBIST PHARMS LLC has six approved drugs.

There are twenty-eight US patents protecting CUBIST PHARMS LLC drugs.

There are three hundred and forty-four patent family members on CUBIST PHARMS LLC drugs in fifty-three countries and fifty-five supplementary protection certificates in eighteen countries.

Summary for Cubist Pharms Llc

International Patents:	344
US Patents:	28
Tradenames:	5
Ingredients:	4
NDAs:	6

Drugs and US Patents for Cubist Pharms Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	TABLET;ORAL	201699-001	May 27, 2011		RX	Yes	Yes
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes	10,065,947		Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes	10,442,829			Y
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	10,028,963
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,968,753

Expired US Patents for Cubist Pharms Llc

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	6,852,689
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	8,058,238
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	RE39071
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	5,912,226
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	8,129,342
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	5,912,226

Paragraph IV (Patent) Challenges for CUBIST PHARMS LLC drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	For Injection	500 mg/vial		2008-11-19
	Tablets	200 mg		2015-05-27

International Patents for Cubist Pharms Llc Drugs

Country	Patent Number	Estimated Expiration
China	100343260
New Zealand	700372
Portugal	1556389
Serbia	57566
South Korea	20150114498
World Intellectual Property Organization (WIPO)	2006130629

Supplementary Protection Certificates for Cubist Pharms Llc Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1699784	15C0062	France		PRODUCT NAME: TEDIZOLIDE,EVENTUELLEMENT SOUS LA FORME D'UN ESTER ,EN PARTICULIER UN PHOSPHATE,OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/15/991 20150325
1115417	22/2006	Austria		PRODUCT NAME: DAPTOMYCIN; REGISTRATION NO/DATE: EU/1/05/328/001 UND 002 20060119
1556389	602	Finland
1556389	92943	Luxembourg		PRODUCT NAME: CEFTOLOZANE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE, EN PARTICULIER UN SEL D'ACIDE SULFURIQUE (ZERBAXA); FIRST REGISTRATION: 20150922
1539977	CR 2015 00020	Denmark		PRODUCT NAME: FIDAXOMICIN; REG. NO/DATE: EU/1/11/733/001-004 20111207
1556389	CR 2016 00004	Denmark		PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cubist Pharms
• Cubist Pharms Llc

Pharmaceutical Competitive Landscape Analysis: Cubist Pharmaceuticals LLC – Market Position, Strengths & Strategic Insights

In the ever-evolving pharmaceutical industry, understanding the competitive landscape is crucial for success. Cubist Pharmaceuticals LLC, a company that made significant strides in the antibiotics market, offers valuable insights into strategic positioning and growth in this sector. Let's dive into an in-depth analysis of Cubist's market position, strengths, and the strategic insights we can glean from their journey.

The Rise of Cubist Pharmaceuticals

Cubist Pharmaceuticals emerged as a key player in the antibiotics market, focusing on addressing the critical need for new treatments against antibiotic-resistant bacteria. Founded in 1992, the company quickly established itself as a leader in developing novel antibiotics for serious infections.

A Focus on Acute Care

Cubist's strategic decision to focus on the acute care market set them apart from many competitors. This niche allowed them to develop expertise in an area of growing importance within the healthcare system.

Cubist's Market Position

By 2014, Cubist had positioned itself as a global leader in antibiotics, with a strong portfolio of both marketed and late-stage pipeline medicines[1]. This positioning made the company an attractive acquisition target for larger pharmaceutical firms looking to bolster their presence in the acute care market.

Key Products and Pipeline

Cubist's flagship product, CUBICIN® (daptomycin for injection), became a cornerstone of their success. By 2014, CUBICIN was expected to exceed $1 billion in U.S. sales alone by 2017[2]. The company's pipeline, including promising candidates like CXA-201, further strengthened their market position.

Strengths of Cubist Pharmaceuticals

Innovative R&D Approach

Cubist's commitment to research and development was evident in their investment strategy. In 2014, the company planned to invest approximately $400 million in antibiotic R&D[3]. This focus on innovation helped maintain their competitive edge in a challenging market.

Strategic Partnerships and Acquisitions

Cubist demonstrated a keen ability to grow through strategic partnerships and acquisitions. Their acquisition of Trius Therapeutics and Optimer Pharmaceuticals in 2013 expanded their product portfolio and pipeline[6].

Global Expansion

Recognizing the global nature of the antibiotic resistance threat, Cubist expanded its international presence. The opening of their international headquarters in Zurich, Switzerland, in 2014 positioned them to better serve global markets[3].

Strategic Insights from Cubist's Journey

Focus on Unmet Medical Needs

Cubist's success underscores the importance of addressing critical unmet medical needs. Their focus on antibiotic-resistant infections aligned with a growing global health concern, driving both their scientific and commercial success.

Long-term Vision

The company's "Building Blocks of Growth" strategy, unveiled in 2012, set ambitious five-year goals, including reaching $2 billion in global annual revenue by 2017[2]. This long-term vision guided their investments and strategic decisions.

"Through our transformation over the past two years, Cubist has established itself as a global leader in the acute care/hospital environment. Our Building Blocks of Growth will help us build on this momentum as we look to deliver important new medicines for patients and drive long-term value for our customers and shareholders," said Mr. Bonney[2].

Balancing Internal R&D and External Growth

Cubist's strategy balanced strong internal discovery efforts with active business development. This approach allowed them to maintain a robust pipeline while also capitalizing on external opportunities.

The Merck Acquisition: A Testament to Cubist's Value

In December 2014, Merck & Co. announced its intention to acquire Cubist Pharmaceuticals for $9.5 billion[1]. This acquisition highlighted the value of Cubist's market position and strategic focus.

Strategic Fit for Merck

For Merck, the acquisition of Cubist aligned with their strategy to strengthen their position in the hospital acute care market. It also demonstrated the renewed interest in the antibiotics market among large pharmaceutical companies.

Lessons for Pharmaceutical Companies

Niche Focus Can Drive Growth

Cubist's success demonstrates that focusing on a specific niche within the pharmaceutical industry can drive significant growth and create substantial value.

Importance of Pipeline Development

The company's strong pipeline, which included four product candidates in late-stage clinical trials by 2017, was a key factor in its attractiveness to Merck[2]. This underscores the importance of continuous innovation and pipeline development.

Adapting to Market Trends

Cubist's focus on hospital-acquired infections and antibiotic resistance aligned with growing market trends and regulatory priorities. This alignment contributed significantly to their success.

The Future of Antibiotic Development

Cubist's journey highlights the ongoing need for innovation in antibiotic development. As antibiotic resistance continues to pose a global health threat, companies that can successfully navigate this challenging market stand to make significant contributions to public health and create substantial value.

Regulatory Environment

The regulatory landscape for antibiotic development has evolved, with initiatives like the GAIN Act in the U.S. providing incentives for companies to invest in this area. Future success in this market will require a deep understanding of these regulatory dynamics.

Competitive Analysis in the Pharmaceutical Industry

Cubist's story underscores the importance of thorough competitive analysis in the pharmaceutical industry. Understanding market trends, competitor strategies, and unmet medical needs is crucial for success.

Tools for Competitive Analysis

Pharmaceutical companies can leverage various tools for competitive analysis, including:

1. SWOT Analysis
2. Porter's Five Forces
3. Patent Landscape Assessment
4. Financial Performance Evaluation

The Role of Data in Competitive Intelligence

In today's data-driven world, leveraging big data and analytics can provide crucial insights for competitive analysis. Real-world evidence, artificial intelligence, and predictive analytics are becoming increasingly important tools in this process[5].

Key Takeaways

• Cubist Pharmaceuticals' success was built on a focused strategy targeting the acute care antibiotics market.
• The company's commitment to R&D, strategic acquisitions, and global expansion drove its growth and market position.
• Cubist's journey highlights the value of addressing unmet medical needs and aligning with market trends.
• The Merck acquisition underscored the value of Cubist's market position and pipeline.
• Competitive analysis, leveraging tools like SWOT analysis and data analytics, is crucial for success in the pharmaceutical industry.
• The antibiotic resistance challenge continues to present opportunities for innovative companies in the pharmaceutical sector.

FAQs

1. What was Cubist Pharmaceuticals' main focus? Cubist Pharmaceuticals focused primarily on developing antibiotics for serious infections, particularly in the acute care/hospital environment.

2. How did Cubist's strategy contribute to its success? Cubist's strategy of focusing on unmet medical needs in antibiotics, investing heavily in R&D, and expanding globally contributed significantly to its success and eventual acquisition by Merck.

3. What can other pharmaceutical companies learn from Cubist's journey? Companies can learn the importance of niche focus, continuous innovation, strategic partnerships, and aligning with market trends and regulatory priorities.

4. Why did Merck acquire Cubist Pharmaceuticals? Merck acquired Cubist to strengthen its position in the hospital acute care market and capitalize on Cubist's expertise and pipeline in antibiotics.

5. How important is competitive analysis in the pharmaceutical industry? Competitive analysis is crucial in the pharmaceutical industry, helping companies identify market opportunities, anticipate trends, and make informed strategic decisions.

Sources cited: [1] https://www.merck.com/news/merck-to-acquire-cubist-pharmaceuticals-for-102-per-share-in-cash/ [2] https://www.biospace.com/cubist-pharmaceuticals-inc-unveils-five-year-strategic-goals [3] https://www.biospace.com/cubist-pharmaceuticals-inc-opens-global-hq-to-invest-approximately-400-million-on-antibiotic-r-and-d [5] https://www.drugpatentwatch.com/blog/the-importance-of-pharmaceutical-competitor-analysis/ [6] https://www.investing.com/equities/cubist-pharmaceuticals